Breaking News
Subscribe Now 0
🧐 ProPicks AI October update is out now! See which stocks made the list Pick Stocks with AI
Close

Aridis Pharmaceuticals Inc (ARDS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.010 0.000    0.00%
22/07 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.010 - 0.010
Aridis Pharma 0.010 0.000 0.00%

Aridis Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Aridis Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

37

Equity Type

ORD

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

Contact Information

Address 983 University Avenue Building B
Los Gatos, 95032
United States
Phone 408 385 1742
Fax 408 356 9548

Top Executives

Name Age Since Title
Steven Michael Opal - - Member Scientific Advisory Board
John F. Hamilton 78 2015 Independent Director
Jean Chastre - 2016 Member of Clinical Advisory Board
Bruno Francois - 2016 Member of Clinical Advisory Board
John S. Patton 75 - Member of the Scientific Advisory Board
Alan H. Cohen 62 2017 Member of Clinical Advisory Board
Marin H. Kollef 66 2016 Member of Clinical Advisory Board
Jerry Pier - - Member of the Scientific Advisory Board
David Salisbury - 2019 Member of Scientific Advisory Board
Harry B. Greenberg - - Member of Scientific Advisory Board
Susan R. Windham-Bannister 72 2019 Independent Director
Vu L. Truong 59 2003 Founder, CEO, Chief Scientific Officer & Director
Eric J. Patzer 74 2003 Founder & Executive Chairman
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ARDS Comments

Write your thoughts about Aridis Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
jansi rani
jansi rani Jul 25, 2023 5:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
it will rise but when it rises, sell or hold it?
van paul le le
van paul le le Feb 10, 2022 7:09PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
all the way baby
van paul le le
van paul le le Feb 10, 2022 7:09PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
yayy
Mehmet Salduz
Mehmet Salduz Jan 27, 2022 5:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
do you think it will rise?🤔
espen eide
espen eide Jan 19, 2022 3:18PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
To the moon 💥👍
Amir Hosein
Amir Hosein Jan 13, 2022 8:36PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
moon go to
Midas Den
Midas Den Jan 07, 2022 1:26PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any future in this?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email